Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Moleculin Biotech ( (MBRX) ) is now available.
On June 20, 2025, Moleculin Biotech commenced a public offering of shares and warrants, closing on June 23, 2025, raising approximately $5.9 million. The proceeds will be used to advance its drug portfolios, including Annamycin, through clinical development. The offering, facilitated by Roth Capital Partners, aims to strengthen Moleculin’s market position in targeting hard-to-treat cancers and viruses.
The most recent analyst rating on (MBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases, avoiding common drug resistance and cardiotoxicity.
Average Trading Volume: 877,285
Technical Sentiment Signal: Sell
Current Market Cap: $3.77M
See more data about MBRX stock on TipRanks’ Stock Analysis page.